Teglicar is used in the research of diabetes and neurodegenerative diseases, including Huntington's disease (HD), due to its potential antihyperglycemic properties as a selective, reversible, and orally active inhibitor of the liver isoform of carnitine palmitoyltransferase 1 (L-CPT1).